SAR3419 (coltuximab ravtansine), an antibody-drug conjugate of maytansinoid DM4 and anti-CD19 antibody, has proven its efficacy preclinically in B-ALL and infant mixed-lineage leukemia (MLL) immune-deficient (NOD/SCID) mice xenografts. This evidence concerns the gene CD19 and leukemia.